Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and Nab-paclitaxel in MIBC
NCT04730219Phase 2Unknown
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Jul 2020
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in muscle-invasive bladder cancer (MIBC), urothelial carcinoma (UC), sponsored by The Second Hospital of Tianjin Medical University. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
muscle-invasive bladder cancer (MIBC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04730219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04730219.